Abstract: The present disclosure is directed to compositions and methods of treating arthritogenic alphavirus infection. Compositions include a fusion protein comprising an Fc region, a first Mxra8 region, and a second Mxra8 region, wherein the fusion protein reduces inflammation and infection by an arthritogenic alphavirus. Methods include administering the fusion protein to a mammalian or non-mammalian subject to reduce or inhibit alphavirus infection.

Abstract: Compositions and methods for treating a viral infection may comprise use of a viral recognition-site inhibiting agent composition. A viral recognition-site inhibiting agent composition of the present disclosure may substantially inhibit, reduce, or block virus bind to the LDLRAD3 host receptor and reduces the infectivity of a virus for a host cell. A method of treating a viral infection may comprise administering a composition comprising a viral recognition-site inhibiting agent of the present disclosure, to a subject and reducing the infectivity of the virus for a host cell of the subject. The compositions may be administered via intranasal or systemic administration to treat or prevent a viral infection, for example an alphavirus infection.

Abstract: Among the various aspects of the present disclosure is the provision of compositions and methods of treating arthritogenic alphavirus infection and methods of screening.